Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis

In a systematic review and meta-analysis, Giovanni Musso and colleagues examine the association between non-alcoholic fatty liver disease and chronic kidney disease. Please see later in the article for the Editors' Summary

[1]  T. Wilt,et al.  Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease. , 2014, Annals of internal medicine.

[2]  Bin Wang,et al.  Simple steatosis is a more relevant source of serum inflammatory markers than omental adipose tissue. , 2014, Clinics and research in hepatology and gastroenterology.

[3]  Paul Shekelle,et al.  Screening, Monitoring, and Treatment of Stage 1 to 3 Chronic Kidney Disease: A Clinical Practice Guideline From the American College of Physicians , 2013, Annals of Internal Medicine.

[4]  Paul Shekelle,et al.  Treatment of Anemia in Patients With Heart Disease: A Clinical Practice Guideline From the American College of Physicians , 2013, Annals of Internal Medicine.

[5]  El-Shazly Abdul Khalek,et al.  Association between nonalcoholic fatty liver disease and the incidence of cardiovascular and renal events. , 2013, Journal of the Saudi Heart Association.

[6]  E. Bjornsson,et al.  Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. , 2013, Gastroenterology.

[7]  T. Hibi,et al.  Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY) , 2013, International journal of endocrinology.

[8]  R. Shaw,et al.  ASSESSMENT OF PUBLICATION BIAS , 2013 .

[9]  A. Levin,et al.  Practice Guideline , 2020, Encyclopedia of Behavioral Medicine.

[10]  G. Navis,et al.  Central body fat distribution associates with unfavorable renal hemodynamics independent of body mass index. , 2013, Journal of the American Society of Nephrology : JASN.

[11]  Myeong Jun Song,et al.  Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease , 2013, Clinical and molecular hepatology.

[12]  L. Appel,et al.  The Effects of n-3 Long-Chain Polyunsaturated Fatty Acid Supplementation on Biomarkers of Kidney Injury in Adults With Diabetes , 2013, Diabetes Care.

[13]  S. Bağcı,et al.  Plasma fetuin‐A is associated with endothelial dysfunction and subclinical atherosclerosis in subjects with nonalcoholic fatty liver disease , 2013, Clinical endocrinology.

[14]  H. Kweon,et al.  Non-alcoholic Fatty Liver Disease and Chronic Kidney Disease in Koreans Aged 50 Years or Older , 2013, Korean journal of family medicine.

[15]  V. Wong,et al.  NAFLD in Asia—as common and important as in the West , 2013, Nature Reviews Gastroenterology &Hepatology.

[16]  M. Budoff,et al.  Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis. , 2013, Atherosclerosis.

[17]  E. Skrzypczak‐Jankun,et al.  Plasminogen activator inhibitor-1 in kidney pathology (Review). , 2013, International journal of molecular medicine.

[18]  Keith C. Norris,et al.  Dysregulation of hepatic fatty acid metabolism in chronic kidney disease. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  Xiaodong Sun,et al.  Serum Fetuin-A Levels Related with Microalbuminuria in Diet-Induced Obese Rats , 2012, BioMed research international.

[20]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration , 2013 .

[21]  A. Prasad.  Can Non-alcoholic fatty liver disease (NAFLD) as a marker for microalbuminuria in prediabetes group? , 2013 .

[22]  G. Wolf,et al.  The role of the renin-angiotensin-aldosterone system in obesity-related renal diseases. , 2013, Seminars in nephrology.

[23]  P. Gill,et al.  Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. , 2013, Journal of hepatology.

[24]  M. Chonchol,et al.  Association between Nonalcoholic Liver Disease and Chronic Kidney Disease: An Ultrasound Analysis from NHANES 1988–1994 , 2012, American Journal of Nephrology.

[25]  A. Hofman,et al.  Renal function‐dependent association of serum uric acid with metabolic syndrome and hepatic fat content in a middle‐aged and elderly Chinese population , 2012, Clinical and experimental pharmacology & physiology.

[26]  Ali Zarrinpar,et al.  Liver Transplantation for Nonalcoholic Steatohepatitis: The New Epidemic , 2012, Annals of surgery.

[27]  E. van Marck,et al.  Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[28]  G. Musso,et al.  Nonalcoholic steatohepatitis versus steatosis: Adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism , 2012, Hepatology.

[29]  J. Bae,et al.  Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepat , 2012, Journal of clinical lipidology.

[30]  K. Cusi,et al.  The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.

[31]  Loreto Gesualdo,et al.  Geographic Differences in Genetic Susceptibility to IgA Nephropathy: GWAS Replication Study and Geospatial Risk Analysis , 2012, PLoS genetics.

[32]  Corri Black,et al.  Measuring the population burden of chronic kidney disease: a systematic literature review of the estimated prevalence of impaired kidney function. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[33]  L. Ferrucci,et al.  Serum Fibroblast Growth Factor 21 Is Associated with Renal Function and Chronic Kidney Disease in Community‐Dwelling Adults , 2012, Journal of the American Geriatrics Society.

[34]  Shang-Jyh Hwang,et al.  Chronic kidney disease prevention—a challenge for Asian countries: report of the Third Asian Forum of Chronic Kidney Disease Initiatives , 2012, Clinical and Experimental Nephrology.

[35]  R. Fogari,et al.  Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis , 2012, European journal of gastroenterology & hepatology.

[36]  H. Cortez‐Pinto,et al.  Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[37]  E. Bonora,et al.  Increased prevalence of chronic kidney disease in patients with Type 1 diabetes and non‐alcoholic fatty liver , 2012, Diabetic medicine : a journal of the British Diabetic Association.

[38]  Guolin Li,et al.  Nonalcoholic fatty liver disease associated with impairment of kidney function in nondiabetes population , 2012, Biochemia medica.

[39]  Z. Soltani,et al.  Lipid Nephrotoxicity: New Concept for an Old Disease , 2012, Current Hypertension Reports.

[40]  A. Sutton,et al.  Assessment of publication bias, selection bias, and unavailable data in meta-analyses using individual participant data: a database survey , 2012, BMJ : British Medical Journal.

[41]  Edgar,et al.  The Effects of n-3 Long-Chain Polyunsaturated Fatty Acid Supplementation on Biomarkers of Kidney Injury in Adults With Diabetes Results of the GO-FISH trial , 2012 .

[42]  G. Musso,et al.  Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials , 2012, Diabetologia.

[43]  I. Kamel,et al.  Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study , 2011, BMJ : British Medical Journal.

[44]  G. Musso,et al.  Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity , 2011, Annals of medicine.

[45]  L. Wong,et al.  Implications of worse renal dysfunction and medical comorbidities in patients with NASH undergoing liver transplant evaluation: impact on MELD and more , 2011, Clinical transplantation.

[46]  S. Kashyap,et al.  Metabolic syndrome and kidney disease: a systematic review and meta-analysis. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[47]  Eliseo Guallar,et al.  Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta‐analysis , 2011, Hepatology.

[48]  Bertram L Kasiske,et al.  Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). , 2011, Kidney international.

[49]  Iris M. Heid,et al.  Chronic Kidney Disease: Novel Insights from Genome-Wide Association Studies , 2011, Kidney and Blood Pressure Research.

[50]  K. Siamopoulos,et al.  The role of obesity in kidney disease: recent findings and potential mechanisms , 2011, International Urology and Nephrology.

[51]  Y. Mori,et al.  Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. , 2011, Metabolism: clinical and experimental.

[52]  Lan He,et al.  Lipid partitioning after uninephrectomy , 2011, Acta Diabetologica.

[53]  A. McCullough,et al.  Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. , 2011, Journal of hepatology.

[54]  J. Higgins.  Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration , 2011 .

[55]  D. Mikhailidis,et al.  Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis , 2010, The Lancet.

[56]  Giuseppe Lippi,et al.  Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[57]  M. Chonchol,et al.  Relationship between serum gamma-glutamyltransferase and chronic kidney disease in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001-2006. , 2010, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[58]  Henry Völzke,et al.  The association between fatty liver disease and blood pressure in a population-based prospective longitudinal study , 2010, Journal of hypertension.

[59]  H. Koide,et al.  Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease , 2010, European journal of clinical investigation.

[60]  Y. Yılmaz,et al.  Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis. , 2010, Metabolism: clinical and experimental.

[61]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[62]  Vincent Wai-Sun Wong,et al.  Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years , 2010, Gut.

[63]  Won-Young Lee,et al.  Impact of non‐alcoholic fatty liver disease on microalbuminuria in patients with prediabetes and diabetes , 2010, Internal medicine journal.

[64]  Y. Yılmaz.  The AGEs-RAGE axis and nonalcoholic steatohepatitis: the evidence mounts , 2010, Journal of Gastroenterology.

[65]  Marcello Tonelli,et al.  Early recognition and prevention of chronic kidney disease , 2010, The Lancet.

[66]  G. Prescott,et al.  Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis. , 2010, Health technology assessment.

[67]  J. Ix,et al.  Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. , 2010, Journal of the American Society of Nephrology : JASN.

[68]  Greger Lindberg,et al.  Decreased survival of subjects with elevated liver function tests during a 28‐year follow‐up , 2010, Hepatology.

[69]  H. Wang,et al.  Smoking Is Associated with Histological Severity in Nonalcoholic Steatohepatitis , 2010 .

[70]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[71]  Tsukasa Nakamura,et al.  Atorvastatin Reduces Proteinuria in Non-Diabetic Chronic Kidney Disease Patients Partly via Lowering Serum Levels of Advanced Glycation End Products (AGEs) , 2010, Oxidative medicine and cellular longevity.

[72]  Richard D Riley,et al.  Meta‐analysis of a binary outcome using individual participant data and aggregate data , 2010, Research synthesis methods.

[73]  J. Ioannidis,et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. , 2009, Journal of clinical epidemiology.

[74]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[75]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[76]  C. Yuan,et al.  Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[77]  F. Casoinic,et al.  Nonalcoholic fatty liver disease--a risk factor for microalbuminuria in type 2 diabetic patients. , 2009, Romanian journal of internal medicine = Revue roumaine de medecine interne.

[78]  Anita M Saran,et al.  Cardiovascular disease in chronic kidney disease , 2008, Therapeutic advances in cardiovascular disease.

[79]  Tom Greene,et al.  Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the Modification of Diet in Renal Disease study equation for estimating glomerular filtration rate (Annals of Internal Medicine (2006) 145, (247-254)) , 2008 .

[80]  G. Lippi,et al.  Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. , 2008, Journal of the American Society of Nephrology : JASN.

[81]  E. Vittinghoff,et al.  A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients , 2008, Hepatology.

[82]  Yoosoo Chang,et al.  Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. , 2008, Metabolism: clinical and experimental.

[83]  C. Schmid,et al.  Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[84]  G. Lippi,et al.  Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients , 2008, Diabetologia.

[85]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.

[86]  Richard D Riley,et al.  Evidence synthesis combining individual patient data and aggregate data: a systematic review identified current practice and possible methods. , 2007, Journal of clinical epidemiology.

[87]  J. Takeda,et al.  Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. , 2007, World journal of gastroenterology.

[88]  Yoosoo Chang,et al.  gamma-Glutamyltransferase as a predictor of chronic kidney disease in nonhypertensive and nondiabetic Korean men. , 2007, Clinical chemistry.

[89]  M. Holmqvist,et al.  Long‐term follow‐up of patients with NAFLD and elevated liver enzymes , 2006, Hepatology.

[90]  Tom Greene,et al.  Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.

[91]  A. Häkkinen,et al.  Overproduction of large VLDL particles is driven by increased liver fat content in man , 2006, Diabetologia.

[92]  A. Collins,et al.  Projecting the number of patients with end-stage renal disease in the United States to the year 2015. , 2005, Journal of the American Society of Nephrology : JASN.

[93]  D. Jacobs,et al.  Serum γ-Glutamyltransferase Was Differently Associated with Microalbuminuria by Status of Hypertension or Diabetes: The Coronary Artery Risk Development in Young Adults (CARDIA) Study , 2005 .

[94]  S. Sanderson,et al.  The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.

[95]  T. Hostetter,et al.  Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. , 2004, Journal of the American Society of Nephrology : JASN.

[96]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[97]  S Duval,et al.  Trim and Fill: A Simple Funnel‐Plot–Based Method of Testing and Adjusting for Publication Bias in Meta‐Analysis , 2000, Biometrics.